472 related articles for article (PubMed ID: 25801840)
1. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A
CNS Neurol Disord Drug Targets; 2015; 14(6):804-10. PubMed ID: 25801840
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
5. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis.
Losy J; Michałowska-Wender G
Acta Neurol Scand; 2002 Jul; 106(1):44-6. PubMed ID: 12067328
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
7. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
[TBL] [Abstract][Full Text] [Related]
8. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
[TBL] [Abstract][Full Text] [Related]
9. Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.
Arababadi MK; Mosavi R; Khorramdelazad H; Yaghini N; Zarandi ER; Araste M; Pourali R; Nekhei Z; Kennedy D
Biomark Med; 2010 Oct; 4(5):755-9. PubMed ID: 20945990
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis.
Petek-Balcı B; Çoban A; Shugaiv E; Türkoğlu R; Ulusoy C; İçöz S; Pehlivan M; Tüzün E; Akman-Demir G; Kürtüncü M; Eraksoy M
Int J Neurosci; 2015 May; 125(5):352-6. PubMed ID: 25026220
[TBL] [Abstract][Full Text] [Related]
11. Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
Tawfik TZ; Gad AH; Mehaney DA; El Nahrery E; Shehata HS; Hashem H; Ghaffar NFA; Shalaby N
J Neurol Sci; 2016 Oct; 369():36-38. PubMed ID: 27653861
[TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.
Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A
Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370
[TBL] [Abstract][Full Text] [Related]
13. Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex.
Taheri M; Ghafouri-Fard S; Solgi G; Sayad A; Mazdeh M; Omrani MD
Cytokine; 2017 Aug; 96():138-143. PubMed ID: 28399486
[TBL] [Abstract][Full Text] [Related]
14. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
Front Immunol; 2018; 9():1240. PubMed ID: 29915590
[TBL] [Abstract][Full Text] [Related]
15. Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
Abdel-Dayem MA; Shaker ME; Gameil NM
J Neuroimmunol; 2019 Dec; 337():577062. PubMed ID: 31521828
[TBL] [Abstract][Full Text] [Related]
16. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.
Bushnell SE; Zhao Z; Stebbins CC; Cadavid D; Buko AM; Whalley ET; Davis JA; Versage EM; Richert JR; Axtell RC; Steinman L; Medori R
Neurology; 2012 Aug; 79(6):531-7. PubMed ID: 22573631
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-17A Levels Vary in Relapsing-Remitting Multiple Sclerosis Patients in Association with Their Age, Treatment and the Time of Evolution of the Disease.
Guerrero-García Jde J; Castañeda-Moreno VA; Torres-Carrillo N; Muñoz-Valle JF; Bitzer-Quintero OK; Ponce-Regalado MD; Mireles-Ramírez MA; Valle Y; Ortuño-Sahagún D
Neuroimmunomodulation; 2016; 23(1):8-17. PubMed ID: 26599431
[TBL] [Abstract][Full Text] [Related]
18. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
19. Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment.
Zhukovsky C; Herman S; Wiberg A; Cunningham JL; Kultima K; Burman J
Acta Neurol Scand; 2021 Jun; 143(6):602-607. PubMed ID: 33626181
[TBL] [Abstract][Full Text] [Related]
20. Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis.
Mohamed MS; Nahrery EMAE; Shalaby N; Hussein M; Aal RAE; Mohamed MM
Mult Scler Relat Disord; 2019 Feb; 28():226-229. PubMed ID: 30623862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
